SLC5A2 and type 2 diabetes mellitus: Several studies of SGLT2 inhibitors for assessment of the cardiovascular outcome are conducting [37], and it was recently reported that the SGLT2 inhibitor empagliflzoin reduces cardiovascular event in T2DM patient with high CVD risk, EMPA-REG OUTCOME trial, around 48 % of subjects were on insulin-combination therapy [38].